SHANGHAI, Dec. 13, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announces that at the 2021 American Society of Hematology ("ASH") Annual Meeting, the Company presented two posters with study results for CT053, an autologous CAR T-cell product candidate against B-Cell Maturation Antigen (BCMA), which include (1) the sustainable efficacy and safety results from the Phase I/II study in China (LUMMICAR-1) and (2) an integrated analysis in participants with relapsed and/or refractory multiple myeloma (R/R MM) by high-risk factors. Details are listed below.